| Old Articles: <Older 2101-2110 Newer> |
|---|
 |
The Motley Fool
June 16, 2005
Stephen D. Simpson |
Media Drug Withdrawal? Are pharmaceutical companies turning away from mass marketing through TV?   |
The Motley Fool
June 15, 2005
Bobby Shethia |
A New Test for Quest The medical testing leader hopes to improve its steady performance via the rapidly growing gene-testing market. But sustained growth will require hefty capital expenditures. Investors, take note. |
The Motley Fool
June 15, 2005
Charly Travers |
Flamel's CEO Must Go Because the biotech firm has disappointed, investors have understandably not rewarded its lousy results. Flamel's shareholders must vote to remove a management road block to the company's success. |
The Motley Fool
June 15, 2005
Brian Gorman |
Cell Therapeutics' Gamble The biotech company's struggles are far from over. Without an approved drug on the market or the certainty of FDA clearance, the firm won't have an easy time finding investors. |
The Motley Fool
June 14, 2005
Rich Duprey |
Chiron's Credit Conundrum Standard & Poor's downgrades the biotech's credit rating on seemingly old news. Why now? |
The Motley Fool
June 14, 2005
Stephen D. Simpson |
Syneron Aims for Cellulite An FDA approval gives Israel's Syneron the lead in non-surgical cellulite treatment. With robust profit margins, that additional revenue could make a big impact on the bottom line. Investors, take note. |
The Motley Fool
June 14, 2005
Bill Mann |
It's Time for a Change at Flamel A dissident shareholder believes that the French medical tech company's management needs shaking up. Reluctantly, we agree. |
HBS Working Knowledge
June 13, 2005
Sara Grant |
From Turf Wars to Learning Curves: How Hospitals Adopt New Technology Turf wars and learning curves influence how new technology is adopted in hospitals. Harvard professors discuss the implications of their research for your organization. |
The Motley Fool
June 13, 2005
W.D. Crotty |
Is Connetics Saving Face? The FDA is making its mark on this specialty pharmaceutical stock, but there are opportunities to rebound. |
The Motley Fool
June 13, 2005
Stephen D. Simpson |
GE Sparks Small Cardiology Companies A defibrillator distribution deal could boost Cardiac Science's sales. Investors who believe that this agreement could be a real catalyst might want to investigate further. |
| <Older 2101-2110 Newer> Return to current articles. |
